- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01283906
A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients (MuGard)
A Randomized, Double-blind Study to Evaluate the Efficacy of MuGard Mucoadhesive Oral Wound Rinse for the Amelioration of Oral Mucositis in Subjects Receiving Chemoradiation Therapy for the Treatment of Cancers of the Head and Neck
This study is a randomized, double-blind, sham-controlled, two-arm study conducted in subjects receiving chemoradiation therapy for the treatment of head and neck cancer to assess the efficacy of MuGard. The study will evaluate the ability of MuGard to reduce the symptoms of oral mucositis. The study includes a treatment period of approximately 7 weeks depending on the subject's prescribed radiation plan.
MuGard is a liquid that is classified as a medical device. It is a hydrated polymer system (oral hydrogel) and is intended for the management of oral mucositis/stomatitis. When gently distributed within the mouth, the mucoadhesive formulation results in the formation of a protective coating over the oral mucosa. Subjects undergoing chemotherapy with radiation for the treatment of head and neck cancer are at high risk of developing oral mucositis as an adverse side-effect of cancer treatment. MuGard was previously shown to reduce the incidence and severity of mucositis in head and neck cancer patients undergoing radiation therapy when compared with data from historical control groups. The purpose of this study is to perform a direct comparison of the effectiveness of MuGard with a control group.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Arizona
-
Mesa, Arizona, United States, 85206
- Ironwood Cancer and Research Centers
-
Scottsdale, Arizona, United States, 85251
- 21st Century Oncology TRC Headquarters
-
-
Arkansas
-
Hot Springs, Arkansas, United States, 71913
- St. Joseph's Mercy Cancer Center- Hot Springs Radiation Oncology
-
-
California
-
Chico, California, United States, 95926
- Enloe Medical Center- Cancer Center
-
Concord, California, United States, 94520
- John Muir Medical Center
-
-
Florida
-
Orlando, Florida, United States, 32806
- MD Anderson Cancer Center Orlando
-
-
Georgia
-
Columbus, Georgia, United States, 31904
- John B. Amos Cancer Center
-
-
Massachusetts
-
Brockton, Massachusetts, United States, 02302
- Signature Healthcare Brockton Hospital
-
-
Nebraska
-
Omaha, Nebraska, United States, 68106
- Missouri Valley Cancer Consortium
-
-
New York
-
Buffalo, New York, United States, 14215
- VA Western New York Health System
-
Poughkeepsie, New York, United States, 12601
- Vassar Brothers Medical Center
-
-
North Carolina
-
Gastonia, North Carolina, United States, 28054
- CaroMont Health Comprehensive Cancer Center
-
Greenville, North Carolina, United States, 27834
- 21st Century Oncology- Carolina Radiation Medicine
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, United States, 15232
- University of Pittsburgh Medical Center
-
-
Washington
-
Bellingham, Washington, United States, 98225
- PeaceHealth St. Joseph Cancer Center
-
Everett, Washington, United States, 98201
- Providence Hospital - Pacific Campus; Flynn Cancer Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53211
- Columbia St. Mary's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects will be included in the study if they:
- Are willing and able to understand and sign an informed consent form (ICF) for the study approved by the Investigator's local or a central Institutional Review Board (IRB) or Independent Ethics Committee (IEC)
- Are males or females aged 18 years or older
- Have recently-diagnosed, pathologically-confirmed cancer of the head and neck (e.g., oral cavity, oropharynx, hypopharynx, larynx; nasopharynx, lips, sinuses, salivary glands, or unknown primary)that will be treated with CRT (with or without induction therapy prior to CRT)
- Have a plan to receive a continuous course of conventional external beam irradiation delivered as single daily fractions of 2.0 Gy to 2.2 Gy with a cumulative radiation dose between 50 Gy and 72 Gy with concomitant chemotherapy. Planned radiation treatment fields must include at least two oral sites (buccal mucosa, floor of mouth, tongue, soft palate) with each site receiving at least 50 Gy
- Have Karnofsky performance score (KPS) >= 80% or Eastern Cooperative Oncology Group (ECOG) score of <= 1 (See Appendix B and C for KPS and ECOG scores respectively)
- Have the ability to comply with the MuGard product insert
Exclusion Criteria:
Subjects will be excluded from participation in the study if they:
- Have major surgical procedure or significant traumatic injury within 2 weeks prior to the initiation of RT or anticipation of need for major surgical procedure during the course of the study
- Have active infectious disease excluding oral candidiasis
- Have presence of oral mucositis
- Have chronic immunosuppression
- Have use of any investigational agent within 30 days of randomization
- Are female subjects who are pregnant or breastfeeding
- Have known allergies or intolerance to MuGard Mucoadhesive Oral Wound Rinse, its ingredients, or the ingredients used in the sham control. The ingredients which appear in either formulation are as follows: benzalkonium chloride, benzyl alcohol, carbopol 971P, citric acid, glycerin, polysorbate 60, phosphoric acid, purified Water, sodium bicarbonate, sodium chloride, sodium saccharin
- Have inability to give informed consent or comply with study requirements
- Are unwilling to or unable to complete the subject diary
- Have any other condition or prior therapy that in the opinion of the Investigator would make the subject unsuitable for the study or unable to comply with follow-up visits
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MuGard
Mucoadhesive Oral Wound Rinse
|
Mucoadhesive Oral Wound Rinse.
5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day
|
Sham Comparator: Control Rinse
Aqueous Control Rinse.
|
Aqueous Control Rinse.
5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the efficacy of MuGard on reducing the symptoms of oral mucositis using an Oral Mucositis Daily Questionnaire (OMDQ)
Time Frame: 7 weeks
|
To evaluate the efficacy of MuGard administered every 3 hours up to six times a day (while awake) over approximately 7 weeks in subjects with head and neck cancers receiving up to a maximum cumulative radiation dose of 72 Gray (Gy) compared to sham control on reducing the symptoms of oral mucositis [area-under-the-curve (AUC) of Oral Mucositis Daily Questionnaire (OMDQ) Mouth and Throat Soreness (MTS) Question 2].
|
7 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the efficacy of MuGard on delaying the onset of oral mucositis symptoms and reducing the impact on health and resource outcomes.
Time Frame: Approximately 7 weeks
|
To evaluate the efficacy of MuGard administered every 3 hours up to six times a day (while awake) in subjects with head and neck cancers receiving up to a maximum cumulative radiation dose of 72 Gy compared to sham control on delaying the onset of oral mucositis symptoms (OMDQ MTS Question 2) and reducing the impact on health and resource outcomes.
|
Approximately 7 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: William Wisbeck, MD, Providence Hospital - Pacific Campus; Flynn Cancer Center
- Principal Investigator: Dimitrios Papadopoulos, MD, Vassar Brothers Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- APC-10U1101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oral Mucositis
-
Ghada zakiNot yet recruiting
-
Air Force Military Medical University, ChinaNot yet recruitingMucositis OralChina
-
University Hospital, ToulouseRecruiting
-
Catalysis SLCompletedMucositis OralRussian Federation
-
Galera Therapeutics, Inc.CompletedRadiation Induced Oral MucositisUnited States, Canada, Puerto Rico
-
Al-Azhar UniversityCompletedStomatitis (Oral Mucositis)Egypt
-
Cairo UniversityNot yet recruitingChemotherapy Induced Oral Mucositis
-
University of Science and Technology, YemenCompletedChemotherapy-induced Oral Mucositis
-
Tata Memorial CentreRecruitingOral Mucositis (Ulcerative)India
Clinical Trials on MuGard
-
Access Pharmaceuticals, Inc.Advanced Clinical Research Services, LLCCompleted
-
Solasia Pharma K.K.Solasia Medical Information Consulting (Shanghai) Co. Ltd.CompletedChemotherapy- and/or Radiation-induced Oral MucositisChina
-
Jonsson Comprehensive Cancer CenterTranslational Research in OncologyCompletedStage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Oral Complications | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast CancerUnited States